First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial

Autor: Zhou, Qing 1, 40, Yu, Yan 2, 40, Xing, Ligang 3, 40, Cheng, Ying 4, Wang, Ying 5, Pan, Yueyin 6, Fan, Yun 7, Shi, Jianhua 8, Zhang, Guojun 9, Cui, Jiuwei 10, Zhou, Jianying 11, Song, Yong 12, Zhuang, Wu 13, Ma, Zhiyong 14, Hu, Yanping 15, Li, Gaofeng 16, Dong, Xiaorong 17, Feng, Jifeng 18, Lu, Shun 19, Wu, Jingxun 20, Li, Juan 21, Zhang, Longzhen 22, Wang, Dong 23, Xu, Xinhua 24, Yang, Tsung-Ying 25, Yang, Nong 26, Guo, Yubiao 27, Zhao, Jun 28, Yao, Yu 29, Zhong, Diansheng 30, Xia, Bing 31, Yang, Cheng-Ta 32, Zhu, Bo 33, Sun, Ping 34, Shim, Byoung Yong 35, Chen, Yuan 36, Wang, Zhen 37, Ahn, Myung-Ju 38, ∗, Wang, Jie 39, ∗∗, Wu, Yi-Long 1, 41, ∗∗∗
Zdroj: In Med 10 January 2025 6(1)
Databáze: ScienceDirect